Profile data is unavailable for this security.
About the company
Hester Biosciences Limited is an India-based animal healthcare company. The Company is principally engaged in manufacturing poultry vaccines, large animal vaccines, and trading poultry, large animal, and petcare health products. It operates through three segments: Poultry Healthcare, Animal Healthcare, and Petcare. The Poultry Healthcare vaccines include Gumboro I, Inactivated Chick ND, Inactivated Coryza, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, and Inactivated IBD. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, and PPR Vaccine - Sungri/96. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Pawfresh, Synoton, Petsglow, and Vitacoat. The Company also operates diagnostic labs for poultry and provides diagnostic kits for sero-surveillance and mastitis prevention for cattle farms. Its manufacturing facility is located at Meda Adraj Village, Mehsana District, Gujarat.
- Revenue in INR (TTM)3.12bn
- Net income in INR234.69m
- Incorporated1987
- Employees642.00
- LocationHester Biosciences LtdPushpak 1st FloorMotilal Hirabhai Road, Panchvati CircleAHMEDABAD 380006IndiaIND
- Phone+91 7 926445107
- Fax+91 7 926445105
- Websitehttps://www.hester.in/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bliss GVS Pharma Ltd | 8.00bn | 634.20m | 13.86bn | 831.00 | 22.14 | 1.37 | 13.91 | 1.73 | 5.94 | 5.94 | 75.55 | 96.05 | 0.6454 | 3.10 | 1.98 | 9,628,987.00 | 5.80 | 6.46 | 7.04 | 8.22 | 50.26 | 43.91 | 8.99 | 9.92 | 3.74 | -- | 0.0825 | 7.92 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
| Remus Pharmaceuticals Ltd | 2.12bn | 215.37m | 13.91bn | 48.00 | 63.21 | 16.01 | 51.74 | 6.54 | 37.34 | 37.34 | 374.91 | 147.42 | 1.46 | 7.61 | 3.56 | 44,270,750.00 | 17.80 | -- | 44.48 | -- | 22.67 | -- | 12.22 | -- | 1.12 | 55.56 | 0.0997 | -- | 371.94 | -- | 153.29 | -- | -- | -- |
| Zota Health Care Ltd | 2.20bn | -346.82m | 14.98bn | 445.00 | -- | 9.42 | -- | 6.80 | -13.20 | -13.20 | 84.28 | 59.92 | 0.8794 | 2.11 | 7.20 | 4,947,045.00 | -13.89 | -1.38 | -17.57 | -1.85 | 51.96 | 35.95 | -15.79 | -1.33 | 0.8357 | -3.46 | 0.3966 | -- | 28.96 | 16.08 | -148.54 | -- | 39.85 | 0.00 |
| Sigachi Industries Ltd | 4.36bn | 660.99m | 16.02bn | 991.00 | 28.50 | 3.39 | 20.60 | 3.68 | 1.69 | 1.69 | 11.11 | 14.15 | 0.6266 | 3.01 | 3.27 | 4,396,491.00 | 9.36 | 14.77 | 13.25 | 19.57 | 50.50 | 50.30 | 14.93 | 14.92 | 1.39 | 6.47 | 0.2576 | 1.61 | 32.08 | 25.34 | 31.34 | 24.64 | 70.35 | -- |
| Jagsonpal Pharmaceuticals Ltd | 2.27bn | 243.00m | 16.91bn | 1.03k | 71.05 | 8.57 | 59.27 | 7.45 | 8.98 | 8.98 | 83.78 | 74.42 | 0.9703 | 5.13 | 9.92 | 2,213,181.00 | 10.39 | 10.95 | 12.40 | 13.29 | 58.16 | 58.13 | 10.71 | 9.21 | 2.60 | 32.84 | 0.0474 | 43.81 | -11.83 | 4.58 | -15.94 | 25.50 | -35.69 | 82.06 |
| JG Chemicals Ltd | 7.57bn | 550.05m | 16.92bn | 56.00 | 29.24 | 3.88 | 27.12 | 2.23 | 14.77 | 14.77 | 202.34 | 111.33 | -- | -- | -- | 135,230,700.00 | -- | -- | -- | -- | 17.29 | -- | 7.56 | -- | 11.46 | -- | 0.0281 | -- | -14.90 | -- | -43.84 | -- | -- | -- |
| Syncom Formulations (India) Ltd | 3.29bn | 331.47m | 18.33bn | 802.00 | 48.03 | 5.85 | 47.62 | 5.57 | 0.406 | 0.406 | 3.49 | 3.34 | 0.8485 | 6.21 | 3.62 | 4,105,761.00 | 8.54 | 7.50 | 10.99 | 10.23 | 38.49 | 34.10 | 10.07 | 9.38 | 4.09 | 12.05 | 0.0435 | -- | 17.45 | 7.12 | 26.13 | 17.95 | -- | -- |
| Beta Drugs Ltd | 3.35bn | 410.00m | 20.04bn | 371.00 | 48.88 | 11.08 | 39.26 | 5.99 | 42.65 | 42.65 | 348.21 | 188.13 | 1.26 | 4.04 | 3.74 | 9,022,873.00 | 15.42 | 15.10 | 23.35 | 22.23 | 39.95 | 39.77 | 12.25 | 12.38 | 1.59 | 17.06 | 0.0953 | 0.00 | 30.21 | 35.01 | 18.62 | 35.29 | -10.89 | -- |
| Windlas Biotech Ltd | 6.96bn | 612.28m | 20.10bn | 1.15k | 32.93 | 4.26 | 24.86 | 2.89 | 29.20 | 29.20 | 331.88 | 225.63 | 1.06 | 6.07 | 4.43 | 6,028,180.00 | 9.30 | -- | 13.64 | -- | 37.52 | -- | 8.80 | -- | 1.61 | 30.61 | 0.0388 | -- | 22.97 | -- | 36.51 | -- | -- | -- |
| Amrutanjan Health Care Ltd | 4.38bn | 475.20m | 20.22bn | 635.00 | 42.60 | 6.79 | 37.54 | 4.62 | 16.43 | 16.43 | 151.37 | 103.00 | 1.19 | 6.89 | 12.85 | 6,893,025.00 | 12.88 | 16.22 | 16.48 | 20.12 | 50.03 | 53.09 | 10.86 | 13.23 | 3.62 | 217.88 | 0.0074 | 18.95 | 10.96 | 10.71 | 12.90 | 12.46 | 26.93 | 16.43 |
| Hester Biosciences Ltd | 3.12bn | 234.69m | 20.29bn | 642.00 | 84.08 | 6.72 | 48.18 | 6.50 | 28.37 | 28.37 | 368.62 | 354.81 | 0.4617 | 1.22 | 3.23 | 4,862,882.00 | 3.89 | 6.15 | 4.91 | 7.69 | 71.13 | 66.64 | 8.42 | 12.83 | 1.22 | 2.85 | 0.4371 | 23.27 | 14.45 | 11.33 | -29.06 | -14.59 | 1.49 | -11.42 |
| SMS Pharmaceuticals Ltd | 7.68bn | 593.38m | 20.41bn | 1.20k | 34.31 | 3.62 | 22.31 | 2.66 | 7.03 | 7.03 | 91.03 | 66.57 | 0.7278 | 1.81 | 4.18 | 6,420,048.00 | 5.55 | 5.43 | 8.40 | 7.33 | 30.10 | 33.30 | 7.62 | 7.87 | 0.7104 | 4.54 | 0.3361 | 6.17 | 35.86 | 8.81 | 805.82 | 4.47 | 8.41 | 9.86 |
| IOL Chemicals and Pharmaceuticals Ltd. | 20.72bn | 1.19bn | 20.44bn | 2.78k | 17.24 | -- | 11.06 | 0.9866 | 20.20 | 20.20 | 353.05 | -- | -- | -- | -- | 7,461,253.00 | -- | 14.91 | -- | 19.45 | 33.96 | 34.54 | 5.72 | 12.00 | -- | 10.06 | -- | 10.59 | -3.80 | 4.82 | -3.39 | -10.70 | 35.27 | -- |
| Panacea Biotec Ltd | 5.50bn | -148.63m | 25.11bn | 1.15k | -- | 3.02 | 125.78 | 4.57 | -2.46 | -2.46 | 90.20 | 135.98 | 0.4374 | 1.10 | 7.87 | 4,799,546.00 | -1.22 | 10.26 | -1.65 | 16.53 | 63.28 | 50.27 | -2.79 | 24.87 | 1.03 | -13.78 | 0.0254 | 0.00 | 21.57 | 4.13 | 96.47 | -- | 74.65 | -- |
| Themis Medicare Ltd | 4.20bn | 529.90m | 26.64bn | 1.54k | 50.32 | 6.47 | 41.63 | 6.34 | 5.75 | 5.75 | 45.63 | 44.76 | 0.7306 | 2.39 | 2.22 | 2,727,670.00 | 9.21 | 11.12 | 12.57 | 16.46 | 64.64 | 60.32 | 12.61 | 14.96 | 1.56 | -- | 0.1651 | 7.59 | 7.74 | 15.75 | -23.51 | -- | 26.73 | -- |
Data as of Nov 25 2024. Currency figures normalised to Hester Biosciences Ltd's reporting currency: Indian Rupee INR
5.54%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Oaklane Capital Management LLPas of 29 Jan 2024 | 430.20k | 5.06% |
| Dimensional Fund Advisors LPas of 31 Jul 2024 | 37.19k | 0.44% |
| SSgA Funds Management, Inc.as of 07 Nov 2024 | 3.28k | 0.04% |
| Dimensional Fund Advisors Ltd.as of 31 Aug 2024 | 334.00 | 0.00% |
| DFA Australia Ltd.as of 30 Sep 2024 | 126.00 | 0.00% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Oct 2024 | 84.00 | 0.00% |
| Bandhan AMC Ltd.as of 31 Oct 2024 | 52.00 | 0.00% |
More ▼
Data from 29 Jan 2024 - 15 Nov 2024Source: FactSet Research Systems Inc.
